SOVREMENNAYa PERORAL'NAYa TERAPIYa EREKTIL'NOY DISFUNKTsII


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

This review article considers the issues of modern treatment of erectile dysfunction using oral drugs. The comparative data on the effectiveness of various phosphodiesterase type 5 inhibitors are presented. Information about the new drug of this group - Cialis (tadalafil) - 5 mg for daily use, is provided. It is emphasized that the innovative concept of therapy of erectile dysfunction with the use of specially designed phosphodiesterase type 5 inhibitor of for everyday application opens up new potentials for the correction of erectile dysfunction.

全文:

受限制的访问

作者简介

N. Akhvlediani

参考

  1. NIH Consensus Conference. JAMA 1993;270(1):83-90.
  2. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. J Urol 1994;151:54-61.
  3. Rosen RC, Fisher WA, Eardley I, et al. Men's Attitudes to Life Events and Sexuality (MALES) Study. The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004;20(5): 607-17.
  4. Глыбочко П.В., Аляев Ю.Г., Ахвледиани Н.Д. и др. Практическая урология. Руководство для врачей. М.: Медфорум. 2012. С. 265-95.
  5. Martin-Morales A, Haro JM, Beardsworth A, Bertsch J, Kontodimas S; EDOS Group. Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS). Eur Urol 2007;51(2):541-50.
  6. Chun J, Carson CC 3rd. Physician-patient dialogue and clinical evaluation of erectil dysfunction. Urol Clin North Am 2001;28:249-58.
  7. Perelman MA. Sex coaching for physicians: Combination treatment for patient and partner. Int J Impot Res 2003;15(5 suppl): S67-74.
  8. Rosen RC, Fisher WA, Eardley I, et al; Men's Attitudes to Life Events and Sexuality (MALES) Study. The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004;20(5):607-17.
  9. Holden CA, Jolley DJ, McLachlan RI, et al. Men in Australia Telephone Survey (MATeS): predictors of men's help-seeking behaviour for reproductive health disorders. Med J Aust 2006;185(8):418-22.
  10. Wright PJ. Comparison of phosphodiesterase type 5 (PDE5) inhibitors. Int J Clin Pract 2006;60(8):967-75.
  11. Kim TE, Kim BH, Kim JR, et al. Effect of food on the pharmacokinetics of the oral phosphodiesterase 5-inhibitor udenafil for the treatment of erectile dysfunction. Br J Clin Pharmacol 2009;68(1):43-6.
  12. Lee J, Pommerville P, Brock G, et al. Physicianrated patient preference and patient- and partner-rated preference for tadalafil or sildenafil citrate: results from the Canadian 'Treatment of Erectile Dysfunction' observational study. BJU Int 2006;98(3):623-29.
  13. Fisher WA, Rosen RC, Eardley I, Sand M, Goldstein I. Sexual experience of female partners of men with erectile dysfunction: the female experience of men's attitudes to life events and sexuality (FEMALES) study. J Sex Med 2005;2(5):675-84.
  14. Dunn ME, Althof SE, Perelman MA. Phosphodiesterase type 5 inhibitors extended duration of response as a variable in the treatment of erectile dysfunction. Int J Impot Res 2007;19(2):119-23.
  15. Washington SL 3rd, Shindel AW. A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy. Drug Des Devel Ther 2010;4:159-71.
  16. Инструкция для специалистов по медицинскому применению препарата Сиалис® 20 мг (тадалафил), П № 014761/01-050309.
  17. Инструкция для специалистов по медицинскому применению препарата Сиалис® 5 мг (тадалафил), ЛП-000133 от 11.01.2011.
  18. Seftel A, Goldfischer E, Kim ED, et al. Onset of efficacy of tadalafil once daily in men with erectile dysfunction: a randomized, double-blind, placebo controlled trial. J Urol 2011;185(1):243-48.
  19. Porst H, Giuliano F, Glina S, et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 2006;50(2):351-59.
  20. Carson CC, Rajfer J, Eardley I, et. The efficacy and safety of tadalafil: an update. BJU Int 2004;93(9):1276-81.
  21. Porst H, Rajfer J, Casab A, et al. Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction. J Sex Med 2008;5(9):2160-69.
  22. Rubio-Aurioles E, Porst H, Kim ED, et al. A Randomized Open-Label Trial with a Crossover Comparison of Sexual Self-Confidence and Other Treatment Outcomes Following Tadalafil Once a Day Vs. Tadalafil or Sildenafil On-Demand in Men with Erectile Dysfunction. J Sex Med 2012;9(5):1418-29.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2013
##common.cookie##